CERo files Series D Preferred Stock designation; regains Nasdaq bid price compliance

CERO THERAPEUTICS HOLDINGS, INC.

Filed Certificate of Designations for Series D convertible preferred stock effective April 22, 2025, part of previously reported securities purchase agreement.
April 24 closing price was $1.11, ending 26 consecutive trading days below $1.00.
No longer imminent risk of failing Nasdaq's minimum bid price requirement, though future risk remains.
Corporate presentation dated April 2025 furnished; exhibit contains no new specific operational or financial data.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

CERO THERAPEUTICS HOLDINGS, INC.: Filed Certificate of Designations for Series D convertible preferred stock (effective 2025-04-22).

Change: charter amendment
Effective: 2025-04-22

Exact text from the filing

On April 22, 2025, CERo Therapeutics Holdings, Inc. (the “Company”) filed the Certificate of Designations of Rights and Preferences of the Series D Preferred Stock (the “Certificate of Designations”) for the purpose of designating and establishing the Company’s Series D convertible preferred stock, par value $0.0001 per share (the “Series D Preferred Stock”).

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

CERO THERAPEUTICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-035535

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.